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RESEARCH ARTICLE
Association of a PAI-1 Gene Polymorphism
and Early Life Infections with Asthma Risk,
Exacerbations, and Reduced Lung Function
Seong H. Cho1,2☯, Jin-Young Min3☯, Dong Young Kim1, Sam S. Oh4, Dara R. Torgerson4,
Maria Pino-Yanes4, Donglei Hu4, Saunak Sen5, Scott Huntsman4, Celeste Eng4, Harold
J. Farber6, William Rodriguez-Cintron7, Jose R. Rodriguez-Santana8, Denise Serebrisky9,
Shannon M. Thyne10, Luisa N. Borrell11, L. Keoki Williams12,13, William DuPont14, Max
A. Seibold15, Esteban G. Burchard4, Pedro C. Avila1, Rajesh Kumar16,17*
1 Division of Allergy-Immunology, Department of Medicine, Northwestern University, Chicago, Illinois, United
States of America, 2 Division of Allergy-Immunology, Department of Internal Medicine, University of South
Florida, Tampa, Florida, United States of America, 3 Department of Otolaryngology, Northwestern
University, Chicago, Illinois, United States of America, 4 Department of Medicine, University of California,
San Francisco, California, United States of America, 5 Division of Biostatistics, Department of Preventive
Medicine, UTHSC, Memphis, Tennessee, United States of America, 6 Department of Pediatrics, Section of
Pulmonology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, United States of
America, 7 Veterans Caribbean Health Care System, San Juan, Puerto Rico, United States of America,
8 Centro de Neumologia Pediatrica, CSP, San Juan, Puerto Rico, United States of America, 9 Pediatric
Pulmonary Division, Jacobi Medical Center, Bronx, New York, United States of America, 10 Department of
Pediatrics, University of California, San Francisco, California, United States of America, 11 Department of
Health Sciences, Lehman College, CUNY, New York, New York, United States of America, 12 Department of
Internal Medicine, Henry Ford Health System, Detroit, Michigan, United States of America, 13 Center for
Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, United States of
America, 14 Department of Biostatistics, Vanderbilt University Medical School, Nashville, Tennessee, United
States of America, 15 Center for Genes, Environment and Health, National Jewish Health, Denver,
Colorado, United States of America, 16 Division of Allergy-Immunology, Department of Pediatrics,
Northwestern University, Chicago, Illinois, United States of America, 17 The Ann and Robert H. Lurie
Children’s Hospital of Chicago, Chicago, Illinois, United States of America




Plasminogen activator inhibitor-1 (PAI-1) is induced in airways by virus and may mediate
asthmatic airway remodeling. We sought to evaluate if genetic variants and early life lower
respiratory infections jointly affect asthma risk.
Methods
We included Latino children, adolescents, and young adults aged 8–21 years (1736 sub-
jects with physician-diagnosed asthma and 1747 healthy controls) from five U.S. centers
and Puerto Rico after excluding subjects with incomplete clinical or genetic data. We evalu-
ated the independent and joint effects of a PAI-1 gain of function polymorphism and bron-
chiolitis / Respiratory Syncytial Virus (RSV) or other lower respiratory infections (LRI) within
the first 2 years of life on asthma risk, asthma exacerbations and lung function.
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Results
RSV infection (OR 9.9, 95%CI 4.9–20.2) and other LRI (OR 9.1, 95%CI 7.2–11.5) were
independently associated with asthma, but PAI-1 genotype was not. There were joint
effects on asthma risk for both genotype-RSV (OR 17.7, 95% CI 6.3–50.2) and genotype-
LRI (OR 11.7, 95% CI 8.8–16.4). A joint effect of genotype-RSV resulted in a 3.1-fold
increased risk for recurrent asthma hospitalizations. In genotype-respiratory infection joint
effect analysis, FEV1% predicted and FEV1/FVC % predicted were further reduced in the
genotype-LRI group (β -2.1, 95% CI -4.0 to -0.2; β -2.0, 95% CI -3.1 to -0.8 respectively).
Similarly, lower FEV1% predicted was noted in genotype-RSV group (β -3.1, 95% CI -6.1 to
-0.2) with a trend for lower FEV1/FVC% predicted.
Conclusions
A genetic variant of PAI-1 together with early life LRI such as RSV bronchiolitis is associ-
ated with an increased risk of asthma, morbidity, and reduced lung function in this Latino
population.
Introduction
Asthma affects more than 25 million people in the United States including 9.3% of all US chil-
dren, with $56 billion in annual healthcare and indirect costs.[1] Studies have suggested a
range of 47 to 95% heritability for asthma,[2–4] with multiple associated genetic variants.[5]
However, the individual effects of these variants are small,[6,7] leading to questions about
whether these genetic influences are more relevant in the broader context of specific environ-
mental exposures.[8] Among the early environmental exposures associated with asthma, viral
respiratory infections are among the most important.[9,10] While interaction between viral ill-
ness and genetic variants on asthma risk has been reported,[11] mechanisms remain unclear.
A gene-infection interaction promoting airway remodeling and lung function decline may
be important both in asthma and generating severe asthma phenotypes. The plasmin and fibri-
nolytic pathway may be particularly relevant in airway remodeling and upper respiratory infec-
tion is associated with increased fibrinogenic activities in subjects with recurrent wheezing or
asthma.[12,13] Specifically, plasminogen activator inhibitor-1 (PAI-1) promotes fibrosis,
[14,15] and blocking of this enzyme prevents extracellular matrix (ECM) deposition.[16,17]
URI increases airway PAI-1 levels, with virus inducing PAI-1 production in human airway epi-
thelial cells.[12] PAI-1 promoter site genetic variants are strongly associated not only with
plasma PAI-1 levels,[18] but also with increased risk of asthma, decreased forced expiratory
volume in 1 second (FEV1), and airway hyperreactivity.[19] [20]
We utilized the Genes-environments and Admixture in Latino Americans (GALA II) study
to test our hypothesis that a PAI-1 polymorphism in combination with infection in early life
may be associated with asthma, asthma severity, and worse lung function.
Materials and Methods
Recruitment
Latino children, adolescents, and young adults aged 8–21 years from five centers (Chicago, Illi-
nois; Bronx, New York; Houston, Texas; San Francisco Bay Area, California; and Puerto Rico)
PAI-1, Early Life Infection, and Asthma
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were enrolled in the GALA II cohort study from 2006 to 2011 (n = 4157 children of whom
2022 had asthma and 2135 were healthy controls). We excluded subjects who had incomplete
genetic or clinical data for relevant covariates (n = 286 asthmatics and 388 controls), yielding
an analyzing sample size of 3483 subjects (1736 with asthma and 1747 without asthma). Fur-
ther details are available on the online supporting information file.
PAI-1 genotyping for rs2227631
Genome-wide genotyping was performed with the Axiom LAT1 array (World Array 4; Affy-
metrix, Santa Clara, Calif) as previously described.[21] The A allele of the promoter site SNP,
rs2227631, for the PAI-1 gene is a gain of function mutation associated with higher plasma lev-
els of PAI-1,[18] and is included in this chip. In initial exploratory analyses, we evaluated the
individual effects of AG and AA genotypes in combination with infection on asthma risk.
While there was a dose effect, numbers were not sufficiently large to separately analyze the AA-
infection group (for example AA-RSV is only 0.9% (31/3446). The AG and AA groups were
combined for the primary analysis. For completeness, a secondary analysis for the primary out-
come of asthma is presented in the E-tables with genotype expressed as GG, AG, and AA.
Bronchiolitis / RSV
Symptomatic bronchiolitis / RSV episodes requiring medical attention within the first 2 years
of life was ascertained by the following question: “Was<CHILD> diagnosed with bronchioli-
tis or RSV before age 2 yrs.”
Other lower respiratory illness
Symptomatic lower respiratory tract illnesses (LRI) requiring medical attention within the first
2 years of life was ascertained by the following question: “Was<CHILD> seen by a doctor for
chest illness before age 2 yrs.”
Subject exposure classification
Subjects were divided into subgroups to identify the independent and joint effects of LRI
requiring medical attention and rs2227631 genotype as follows: GG without LRI (GG-No LRI),
AG/AA without any history of LRI (AG/AA No LRI), GG with history of LRI (GG+LRI), and
AG/AA with history of LRI (AG/AA+LRI). A similar grouping was carried out for genotype
and symptomatic bronchiolitis / RSV, with “no RSV” indicating that there was no severe symp-
tomatic RSV bronchiolitis requiring medical attention (i.e. no severe RSV).
Outcome measures
The primary outcome was report of physician diagnosed asthma. Secondary outcomes
included asthma exacerbations and lung function. Spirometry was performed using a KoKo
spirometer (nSpire Health, Longmont, CO) according to the guidelines of the American Tho-
racic Society/European Respiratory Society. Measures analyzed included percent predicted
FEV1, FVC, and FEV1/FVC ratio (National Health and Nutrition Examination Survey III ref-
erence standards). Subjects with asthma were categorized for exacerbation status based on each
the following criteria assessed over the previous 12 months: oral steroid use for 2 or more
weeks, 2 emergency room (ER) visits, and 2 hospital admissions.
PAI-1, Early Life Infection, and Asthma
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Replication cohort
The Study of African Americans, Asthma, Genes & Environments II (SAGE II) was used to
replicate the associations found in the GALA II study and is described elsewhere.[22] Briefly,
the SAGE II study is an ongoing clinic-based multicenter asthma case-control study, including
African American subjects with asthma (n = 666) recruited from the San Francisco bay area,
conducted in parallel to GALA II using identical protocols and questionnaires.
Statistical analysis
For descriptive statistics, the study population was divided into asthma and control subjects,
and χ2 tests and t tests performed to describe differences in terms of demographic and clinical
characteristics. Analyses on the outcome of asthma diagnosis included all subjects. However,
asthma exacerbations and lung function analyses were limited to subjects with asthma. Sepa-
rate logistic regression analyses were performed to estimate the associations of asthma with the
PAI-1 genotype at the rs2227631 locus, early-infection (RSV or LRI) history, and the joint effect
of genotype and infection. Similar logistic regression analyses were carried out for the outcome
of asthma exacerbations limited to subjects with asthma. Both analyses controlled for age, sex,
ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal expo-
sure, received antibiotics during first year), family history of asthma, African and European
genetic ancestry, and recruitment site. For the analysis of lung function (percent predicted val-
ues) within asthmatics we used a multivariate linear regression model, adjusting for age, sex,
ethnicity, socioeconomic factors, environmental factors (history of smoke exposure), medica-
tion for asthma control, and recruitment site. Lung function analyses which included the SNP
or SNP-infection analyses also controlled for ancestry. For the asthma analyses, separate mod-
els were also generated to test for the significance of interaction terms for infection and risk
genotype, including terms for the main effects of genotype risk allele and infection history.
Replication of these analyses was carried out in the SAGE study using the same approach.
All statistical analyses were performed using SPSS software (Version 22.0, Statistical Package
for Social Science, Chicago, IL, USA). P values< 0.05 were considered statistically significant.
This study was approved by the institutional review boards at each study center (IRB for
USCF, IRB for Northwestern University, IRB for The Ann and Robert H. Lurie Children’s Hos-
pital of Chicago, IRB for IRB for Texas Children’s Hospital Baylor College of Medicine, IRB for
Veteran’s Caribbean Health Care System, IRB for Centro Neumologica Pediatrica, IRB for
Jacobi Medical Center, IRB for CUNY). Written informed consent was obtained from the
parents or legal guardians of all children and adult participants, and written informed assent
was obtained from all children aged 12–18 years.
Data used in the performance of this analysis is included with the paper in S1 File.
Results
Baseline characteristics
Table 1 presents the distribution of selected characteristics for the overall study sample divided
by asthma status. The mean age of the study population was 13 years and majority of partici-
pants were Mexicans (36.5%) or Puerto Rican (42.6%). Compared to those without asthma,
subjects with asthma were more likely to have had a symptomatic episode of RSV bronchiolitis
or other symptomatic lower respiratory illness before age 2 years old (9.3% vs 0.9%; or 55.4%
vs 10.1%, respectively), but there was no significant difference in PAI-1 genotype. Other differ-
ences by asthma status were minor in magnitude and are described in the online supplement.
PAI-1, Early Life Infection, and Asthma
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Table 1. Demographic and clinical characteristics of subjects.
Variable Total (n = 3483) Asthma (n = 1736) Non-asthma (n = 1747) P value
Age, mean (SD), years 13.18 (3.49) 12.60 (3.32) 13.75 (3.56) 0.000 a
Male, No (%) 1735 (49.8) 961 (55.4) 774 (44.3) 0.000 b
BMI, mean (SD) 23.51 (6.66) 23.25 (6.56) 24.60 (6.93) 0.000 a
Ethnicity, No (%)
Mexican 1271 (36.5) 602 (34.7) 669 (38.3) 0.027 b
Puerto Rican 1485 (42.6) 735 (42.3) 750 (42.9) 0.724
Other Latino 620 (17.8) 338 (19.5) 282 (16.1) 0.010 b
Mixed Latino 106 (3.0) 61 (3.5) 45 (2.6) 0.107
Ancestry proportion, mean (SD)
African 0.14 (0.13) 0.15 (0.13) 0.13 (0.12) 0.000 a
European 0.59 (3.81) 0.54 (0.19) 0.65 (5.37) 0.216
Country born: USA, No (%) 1703 (49.6) 732 (43.0) 971 (56.2) 0.000 b
Recruited center, No (%)
IL 639 (18.4) 310 (17.9) 329 (18.8) 0.492
TX 365 (10.5) 197 (11.4) 168 (9.6) 0.087
NY 545 (15.7) 290 (16.8) 255 (14.6) 0.078
SF 636 (18.3) 317 (18.3) 319 (18.3) 0.955
PR 1289 (37.1) 614 (35.5) 675 (38.7) 0.056
Frequency of allergic sensitization 1809 (52) 1076 (62) 733 (42)
Family history of Asthma, No (%)
Mother 771 (22.8) 561 (33.1) 210 (12.4) 0.000 b
Father 463 (14.4) 334 (20.8) 129 (8.0) 0.000 b
Siblings 1343 (41.6) 866 (53.4) 477 (29.8) 0.000 b
Infection history before age 2 yrs, No (%)
RSV bronchiolitis 177 (5.1) 161 (9.3) 16 (0.9) 0.000 b
LRI 1126 (32.7) 952 (55.4) 174 (10.1) 0.000 b
Environments
Pet exposure during 1st yr of life, No (%)
Cat 371 (10.8) 179 (10.4) 192 (11.1) 0.501
Dog 1165 (33.8) 542 (31.4) 623 (36.1) 0.003 b
Farm animals 358 (10.4) 148 (8.6) 210 (12.1) 0.001 b
Smoke, No (%)
Mother smoke during pregnancy 168 (4.9) 97 (5.6) 71 (4.1) 0.039 b
Adults smoke before age 2yrs 784 (25.3) 437 (27.7) 347 (22.8) 0.002 b
Children ever tried smoking 150 (4.3) 58 (3.3) 92 (5.3) 0.005 b
Children current smoking 1 (0.1) 0 (0.0) 1 (0.2) 0.450
Received antibiotics during 1st yr of life, No (%) 1288 (41.7) 774 (49.7) 514 (33.6) 0.000 b
Daycare, No (%) 812 (23.8) 443 (25.9) 369 (21.7) 0.004 b
Socioeconomic characteristics
Mother education, No (%)
< High school 1356 (38.9) 656 (37.8) 700 (40.1) 0.168
High school 913 (26.2) 471 (27.1) 442 (25.3) 0.219
Some college 1214 (34.9) 609 (35.1) 605 (34.6) 0.781
Income, No (%)
< $25,000 1227 (35.2) 623 (35.9) 604 (34.6) 0.417
$25–75,000 1195 (34.3) 634 (36.5) 561 (32.1) 0.006 b
> $75,000 1061 (30.5) 479 (27.6) 582 (33.3) 0.000 b
(Continued)
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Risk of asthma
Table 2 presents 2 separate models evaluating the effect of genotype, and infection (tested sepa-
rately). Firstly, the PAI-1 SNP rs2227631 itself does not increase the odds of developing asthma.
Second, there was a significant increase in the likelihood of asthma in subjects with a history of
early life infection such as RSV bronchiolitis and other LRI (OR 9.9, 95% CI 4.9–20.2; OR 9.1,
95% CI 7.2–11.5, respectively). If the presence of either RSV or LRI was tested in a similar
model, the findings were unchanged (OR 10.1, 95% CI 8.2–12.4). In Figs 1 and 2, we display
the joint association of the PAI-1 risk genotype and early life infection with the diagnosis of
asthma. While there was an increase of asthma risk in GG-RSV group, there was an even more
dramatic increase in the AG/AA+RSV group (Fig 1—OR 4.1, 95% CI 1.5–11.2; OR 17.7, 95%
CI 6.3–50.2, respectively). Similar findings of lesser magnitude were noted in the GG+LRI
group and AG/AA+LRI group when compared to GG no LRI group (Fig 2—OR 7.7, 95% CI
5.5–11.0; OR 11.7, 95% CI 8.8–16.4, respectively). In models testing the interaction terms for
LRI-genotype and RSV-genotype (accounting for main effects), the LRI-genotype interaction
term was significant at a level of P = 0.014 and the RSV-genotype approached significance at a
Table 1. (Continued)
Variable Total (n = 3483) Asthma (n = 1736) Non-asthma (n = 1747) P value
Insurance, No (%) 2195 (93.1) 1631 (95.2) 1564 (91.0) 0.000 b
rs2227631, No (%)
GG 1405 (40.3) 676 (38.9) 729 (41.7) 0.093
AG 1583 (45.4) 801 (46.2) 782 (44.8) 0.414
AA 495 (14.3) 259 (14.9) 236 (13.5) 0.233
AG+AA 2078 (59.7) 1060 (61.1) 1018 (58.3) 0.093
Lung function, mean (SD)
FEV1% predicted (pre-BD) 92.45 (15.65) 91.03 (16.03) 98.65 (12.04) 0.000
a
FVC% predicted (pre-BD) 96.03 (15.62) 95.55 (16.17) 98.14 (12.78) 0.000 a
FEV1/FVC ratio % predicted (pre-BD) 96.53 (8.86) 95.54 (9.00) 100.86 (6.70) 0.000
a
BMI, body mass index; IL, Illinois; TX, Texas; NY, New York; SF, San Francisco; PR, Puerto Rico; RSV, respiratory syncytial virus; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; BD, bronchodilator
a P < 0.05 from the t test for Asthma vs Non–Asthma.
b P < 0.05 from the χ2 test for Asthma vs Non–Asthma.
doi:10.1371/journal.pone.0157848.t001
Table 2. Adjusted effects of rs2227631, and infection on asthma.
Analyses N OR* (95% CI) P value†
Genotype alone—rs2227631
GG 1405 Reference
AG/AA 2078 1.051 (0.878–1.259) 0.588
Infection history before age 2 yrs alone
RSV bronchiolitis 177 9.920 (4.881–20.159) 0.000
LRI 1126 9.110 (7.233–11.474) 0.000
OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus
*Adjusted for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm
animal exposure and received antibiotics during first year), family history of asthma and recruitment site.
†P values from multivariate regression analysis. Statistically significant P values are indicated in bold.
doi:10.1371/journal.pone.0157848.t002
PAI-1, Early Life Infection, and Asthma
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level of p = 0.08. Furthermore, in a subgroup analysis limited to subjects who had RSV or LRI,
there was a clear genotype effect for the risk allele (AG/AA+RSV OR 4.3, 95% CI 1.04–17.95;
AG/AA+LRI OR 1.58, 95% CI 1.06–2.34) compared to those who had RSV or LRI with the
wild type GG allele. Finally, we also carried out a sensitivity analysis (since RSV was by report)
whereby we combined those with either RSV or LRI by these definitions and found that the
magnitude of effect was similar for the AA/AG+ either LRI or RSV (OR 12.9, 95% CI 9.6–
17.3). The interaction term for any lower respiratory infection and genotype (accounting for
main effects) was significant at the P = 0.002 level.
Asthma Exacerbations
Table 3 presents 3 separate models (limited to subjects with asthma) evaluating the effect of
genotype, infection, and then the joint effect of genotype and infection on asthma severity
using three different parameters: steroid use 2 weeks, ER visit 2 times, and
hospitalization  2 times all in the previous12 months. Considered the effect of genotype
alone, the AG/AA genotype showed more than 2 times higher risk of hospitalization
(P = 0.046, OR 2.2 95% CI 1.0–4.6). Similarly, subjects with a history of RSV bronchiolitis had
Fig 1. Joint association of bronchiolitis/ RSV and PAI-1 risk genotype (rs2227631) with Asthma.RSV indicates subjects who were
diagnosed with bronchiolitis or RSV before age 2 years old. Adjusted for age, sex, ethnicity, ancestry, socioeconomic factors,
environmental factors (history of farm animal exposure and received antibiotics during first year), family history of asthma and
recruitment site.
doi:10.1371/journal.pone.0157848.g001
PAI-1, Early Life Infection, and Asthma
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significantly higher risk of having an ER visit 2 times in the previous 12 months (P = 0.001,
OR 2.0 CI 95% 1.3–3.1). While findings were similar in direction for LRI, they failed to reach
significance (P = 0.18, OR 1.2 95% CI 0.92–1.6, respectively). Finally, the PAI-1 SNP and RSV
jointly increased the risk of ED visits and the risk of hospitalization by 1.8 and 3.1-fold respec-
tively. However, there was no joint effect between the PAI-1 SNP and LRI on these asthma
severity parameters.
Lung function
Table 4 presents 3 separate models (limited to subjects with asthma) evaluating the effect of
genotype, infection, and then the joint effect of genotype and infection on lung function includ-
ing three parameters; FEV1% predicted, FVC % predicted, and FEV1/FVC % predicted. Only
the FEV1/FVC ratio was reduced in AG/AA genotype compared to GG genotype. Early life his-
tory of LRI was associated with decreases in FEV1/FVC ratio; but this was not significant for
RSV bronchiolitis. When we looked at the joint effect of PAI-1 genotype-and early life infec-
tions, FEV1% predicted, and FEV1/FVC % predicted were further reduced in AG/AA+LRI
group compared to GG no LRI group (P = 0.03, coefficient β -2.06 95% CI -3.97–-0.16; and
P = 0.001, coefficient β -1.97 95% CI -3.10–-0.84, respectively). Similar findings were noted in
Fig 2. Joint association of early life lower respiratory tract infection and PAI-1 risk genotype (rs2227631) with Asthma. LRI
indicates subjects who were diagnosed with a lower respiratory tract infection requiring medical attention before age 2 years old. Adjusted
for age, sex, ethnicity, ancestry, socioeconomic factors, environmental factors (history of farm animal exposure and received antibiotics
during first year), family history of asthma and recruitment site.
doi:10.1371/journal.pone.0157848.g002
PAI-1, Early Life Infection, and Asthma
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the analyses of RSV with lower FEV1% predicted in AG/AA-RSV group. The findings for
FEV1/FVC % predicted neared significance but showed a similar magnitude and direction of
findings.
Replication
We evaluated the asthma associations in the SAGE cohort with similar results. The SNP itself
was not associated with asthma (OR 1.27, 95% CI 0.85–1.88), while both RSV (OR 14.3, 95%
CI 1.71–119.53) and LRI (OR 22.1, 95% CI 11.8–41.4) were associated. We also replicated the
joint effects for SNP-LRI association. While there was an increase of asthma risk in GG-LRI
group, there was an even more dramatic increase in the AG/AA+LRI group (OR 20.4, 95% CI
8.9–46.9; OR 26.7, 95% CI 11.2–63.9, respectively). Despite a similar direction and magnitude
of association, we were not able to replicate the SNP-RSV associations in the smaller SAGE
cohort due to small numbers (n = 9) in this sub-group (OR 5.81, 95%CI 0.54–62.3 for AA/AG
+RSV group). We also were not able to replicate the exacerbation and lung function associa-
tions in SAGE, possibly due to the smaller sample size.
Discussion
This study examines the effect of a common polymorphism in the PAI-1 gene and early life
lower respiratory infections including RSV/bronchiolitis in patients with asthma. While the
genotype itself was not associated with asthma risk, there was a significant interaction between
Table 3. Adjusted effect of rs2227631, infection and rs2227631 gene-infection interaction on asthma exacerbations.
Analyses Steroid use 2 weeks in past
12months
ER visit 2 times in past 12months Hospitalizations 2 timesin past
12months
OR* (95%CI) P† OR* (95%CI) P† OR* (95%CI) P†
Genotype alone—rs2227631
GG Reference Reference Reference
AG/AA 1.078 (0.774–1.501) 0.66 0.931 (0.713–1.216) 0.60 2.152 (1.013–4.572) 0.046
Infection history before age 2 yrs alone
RSV bronchiolitis 1.243 (0.800–1.931) 0.33 2.004 (1.314–3.057) 0.001 1.589 (0.740–3.412) 0.23
LRI 1.262 (0.910–1.752) 0.16 1.197 (0.917–1.562) 0.18 1.285 (0.670–2.464) 0.48
Gene-Infection analyses
rs2227631-RSV
GG No RSV Reference Reference Reference
AG/AA No RSV 1.089 (0.765–1.550) 0.63 0.911 (0.689–1.204) 0.51 1.728 (0.794–3.761) 0.17
GG+RSV 1.255 (0.529–2.977) 0.61 2.408 (1.053–5.506) 0.04 ‡ 0.99
AG/AA+RSV 1.274 (0.734–2.211) 0.39 1.854 (1.111–3.092) 0.02 3.107 (1.143–8.450) 0.03
rs2227631- LRI
GG No LRI Reference Reference Reference
AG/AA No LRI 0.954 (0.547–1.664) 0.87 0.709 (0.469–1.069) 0.10 2.075 (0.566–7.602) 0.27
GG+LRI 1.115 (0.634–1.961) 0.71 0.859 (0.561–1.315) 0.49 1.195 (0.278–4.970) 0.80
AG/AA+ LRI 1.278 (0.758–2.155) 0.36 0.991 (0.668–1.472) 0.96 2.645 (0.750–9.334) 0.13
OR, odds ratio; CI, confidence interval; RSV, respiratory syncytial virus
*Adjusted for age, sex, ethnicity, socioeconomic factors, environmental factors (history of smoke exposure), medication for asthma control and recruitment
site. Analyses of SNP and SNP-infection also controlled for ancestry.
†P values from multivariate regression analysis. Statistically significant P values are indicated in bold.
‡ unable to estimate stable odds ratio due to small cell size.
doi:10.1371/journal.pone.0157848.t003
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early life infection and genotype on the outcome of asthma diagnosis. Asthma risk increased
17-fold when this genotype was present in individuals with symptomatic RSV / bronchiolitis
infection and almost12-fold in those with other LRI in early life requiring medical attention.
This finding was replicated in the SAGE II cohort for LRI, but not RSV potentially due to the
small numbers of SAGE II subjects in the AG/AA+RSV group. Both LRI and RSV infection
severe enough to require medical attention (10% and 1% of our control subjects respectively)
and the genotype in question are common.[23,24] The frequencies of AG and AA genotypes
were 45.4% and 14.3%; with an overall A allele frequency of 37%.
The joint effect of early life lower respiratory tract infection and the gain of function PAI-1
SNP is in keeping with other studies which suggest that the PAI-1 pathway is important in air-
way response to virus, and that an exaggerated response may be detrimental. PAI-1 plasma lev-
els are increased in young children who had history of URI-induced repeated wheeze.[13]
Human rhinovirus infection increases the production of PAI-1 in primary airway epithelial
cells from subjects with asthma, and during an URI in subjects with asthma, nasal lavage and
sputum PAI-1 levels increase.[12] These findings serve as in vitro and in vivo evidence of
impact of respiratory viral infections on PAI-1 production in asthma. In murine models, PAI-1
deficiency protected against airway fibrosis, whereas PAI-1 overexpression enhanced fibrotic
changes.[14,15] Blocking PAI-1 using either siRNA for PAI-1 or a PAI-1 inhibitor reduced air-
way inflammation, tissue remodeling and airway hyperreactivity.[16,17]
The rs2227631 SNP itself had significant influence on the FEV1/FVC ratio within our asth-
matic subjects, which is contrast to the findings that this SNP alone was not associated with
asthma risk. We did not have sufficient lung function data for non-asthmatic subjects to deter-
mine whether there is an effect in normal subjects who would presumably have less airway
Table 4. Adjusted effect of rs2227631, infection and rs2227631gene-infection interaction on lung function in asthmatic subjects.
Analyses FEV1% predicted FVC% predicted FEV1/FVC ratio % predicted
Coefficient β* (95% CI) P† Coefficient β* (95% CI) P† Coefficient β* (95% CI) P†
Genotype alone—rs2227631
GG Reference Reference Reference
AG/AA -1.212 (-2.530–0.105) 0.07 -0.517 (-1.812–0.778) 0.43 -0.787 (-1.570 –-0.003) 0.049
Infection history before age 2 yrs alone
RSV bronchiolitis -1.854 (-4.315–0.606) 0.14 -1.032 (-3.458–1.393) 0.40 -0.988 (-2.430–0.453) 0.18
LRI -1.195 (-2.528–0.138) 0.08 -0.060 (-1.256–1.370) 0.93 -1.311 (-2.090 –-0532) 0.001
Gene-Infection analyses
rs2227631-RSV
GG No RSV Reference Reference Reference
AG/AA No RSV -1.051 (-2.414–0.312) 0.13 -0.299 (-1.639–1.041) 0.66 -0.844 (-1.655 –-0.338) 0.04
GG+RSV 0.303 (-3.794–4.400) 0.88 1.005 (-3.024–5.033) 0.62 -0.848 (-3.285–1.589) 0.49
AG/AA+RSV -3.113 (-6.050 –-0.177) 0.04 -1.741 (-4.628–1.146) 0.23 -1.601 (-3.347–0.146) 0.07
rs2227631-LRI
GG No LRI Reference Reference Reference
AG/AA No LRI -0.757 (-2.546–1.032) 0.41 -1.000 (-2.759–0.758) 0.26 0.243 (-0.816–1.301) 0.65
GG+LRI -0.326 (-2.382–1.731) 0.75 -0.348 (-2.369–1.673) 0.74 -0.095 (-1.122–1.311) 0.88
AG/AA+ LRI -2.063 (-3.971 –-0.155) 0.03 -0.234 (-2.109–1.641) 0.81 -1.971 (-3.101 –-0.843) 0.001
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BD, bronchodilator; CI, confidence interval; RSV, respiratory syncytial virus
*Adjusted for BMI, socioeconomic factors, medication for asthma control and recruitment site. Lung function parameters (% predicted values) were already
adjusted with age, sex, and race. Additionally genotype and genotype-infection analyses were corrected for ancestry.
†P values from multivariate regression analysis. Statistically significant P values are indicated in bold.
doi:10.1371/journal.pone.0157848.t004
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inflammation and less remodeling potential. Furthermore, early childhood lower respiratory
tract infection and the SNP had a joint effect on FEV1 and the FEV1/FVC ratio. These findings
raise the question of whether the rs2227631 SNP, in the context of viral insult, may cause
increased production of airway PAI-1 enough to affect lung development in infants and cause
structural airway changes that lead to lower lung function in subjects with asthma.
This study has a number of limitations. While there was a dose effect for A alleles in our pre-
liminary analyses, our numbers were not sufficiently large to analyze the AA-infection group
separately for RSV bronchiolitis. AG and AA groups were combined for the primary analysis to
provide more precise and stable estimates. Secondly, both the PAI-1 SNP rs2227631 [18,25]
and the 4G/5G polymorphism are promoter site polymorphisms [19,20,26] in strong linkage
disequilibrium (D’ = 0.97),[18] making it difficult to determine which is functional even if the
4G/5G variant had been sequenced. However, others have used the rs2227631 genotype as a
proxy for the 4G/5G locus, and found it to be the variant which was most highly associated
with PAI-1 levels on GWAS analysis, suggesting that this may be the more important locus.
[27] Third, the exposures of RSV/ bronchiolitis and LRI were based on a self-report question-
naire designed to elucidate infections resulting in lower respiratory symptoms in a child under
the age of 2 years. This is based on the fact that most childhood respiratory illness is indeed
due to viral pathogens as has been shown by the Hartert group.[24] While, it is also possible
that a recall bias would have resulted in only more severe illnesses were reported, this is in
keeping with our focus. Severe enough illness to require a visit to the physician increase the rel-
evance of inflammation and PAI-1. Even if some subjects with less severe illness were systemat-
ically included in the “no severe infection group”, this would bias our analysis towards the null
hypothesis, making our findings even more robust. Finally, it is also possible that asthmatic
subjects may have greater recall of early wheezing illnesses which may increase the magnitude
of the wheezing illness–asthma association. However, this effect should not bias the effect of
genotype on asthma when studied within these symptomatic subjects as was evaluated in the
subgroup analysis. This effect was clearly present, in contrast to the main analysis, which
showed no genotype effect. Furthermore, other viruses may have caused symptomatic bronchi-
olitis and termed “RSV” by health care providers.[24] Over 70% of bronchiolitis is associated
with RSV,[24] with most severe bronchiolitis associated with RSV or RSV/rhinovirus co-infec-
tion.[28] Thus, RSV is likely to be further enriched in this group beyond 70%. Regardless, our
analyses were also consistent for LRI, a proof of the general principle. The importance of any
early viral illness in the development of asthma in a susceptible host is underscored by a recent
report that all viruses resulting in symptomatic illnesses in the first year of life (not just RV or
RSV), increased the risk of asthma by age 7.[29]
Conclusion
In conclusion, a genetic variant of PAI-1 which increases PAI-1 production, together with
either early life lower respiratory infection, was associated with asthma diagnosis, asthma exac-
erbations, and asthma severity based on reduced FEV1/FVC ratio in our Latino population.
The asthma associations for genotype-LRI were replicated in a smaller African American pop-
ulation. Further prospective studies are needed to replicate our RSV-genotype findings in other
non-latino populations, and determine if PAI-1 variants may serve as a biomarker of risk,
which may provide impetus for clinical trials of primary prevention of asthma. In the interim,
PAI-1 genotype in combination with significant LRI, identifies individuals at increased risk of
developing asthma. Studies are needed to determine whether interventions affecting airway
responses at time of early life LRI in these at risk individuals will decrease the chances of devel-
oping asthma.
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